H9X-MC-GBGJ Statistical Analysis Plan Version 1
A Phase
 2, Double -Blind, Placebo- Controlled, 18- Week Trial  of Investigational Dula glutide 
Doses versus Placebo in Patients with Type 2 Diabetes on Metformin Monotherapy 
[STUDY_ID_REMOVED] 
Approval Date: 08-Dec-2016 
H9X- MC- GBGJ  S ta t is t ica l  Ana lys is  P lanVe rs ion  1 Page  1
LY21892651 .S ta t is t ica l  Ana lys is  P lan :  
H9X- MC- GBGJ:  A  Phase  2 ,  Doub le- B l ind ,  P lacebo-
Con t ro l led ,  18- Week  T r ia l  o f  Inves t iga t iona l  Du lag lu t ide
Doses  ve rsus  P lacebo  in  Pa t ien ts  w i th  Type  2  D iabe tes  
on  Me t fo rm in  Mono the rapy
Con f iden t ia l  In fo rma t ion
The  in fo rma t ion  con ta ined  in  th isdocumen tis  con f iden t ia l  and  the  in fo rma t ion  con ta ined  
w i th in  i t  may  no t  be  rep roduced  o r  o the rw ise  d issem ina ted  w i thou t  the  app rova l  o f  E l i  L i l ly  
and  Company  o r  i ts  subs id ia r ies .   
No te  to  Regu la to ry  Au tho r i t ies:   Th is  documen t  may  con ta in  p ro tec ted  pe rsona l  da ta  
and /o r  comme rc ia l ly  con f iden t ia l  in fo rma t ion  exemp t  f rom  pub l ic  d isc losu re .  E l i  L i l ly  and  
Company  reques ts  consu l ta t ion  rega rd ing  re lease / redac t ion  p r io r  to  any  pub l ic  re lease .  In  
the  Un i ted  S ta tes ,  th is  documen t  is  sub jec t  to  F reedom  o f  In fo rma t ion  Ac t  (FO IA )  
Exemp t ion  4  and  may  no t  be  rep roduced  o r  o the rw ise  d issem ina ted  w i thou t  the  w r i t ten  
app rova l  o f  E l i  L il ly  and  Company  o r  i ts  subs id ia r ies .
Du lag lu t ide(LY 2189265)T2D
S tudy  H9X- MC- GBGJ  is  a  Phase  2 ,  random ized ,  doub le- b l ind ,  p lacebo- con t ro l led  t r ia l  
des igned  to  assess  the  e f f icacy  and  sa fe ty  o f  once- week ly  inves t iga t iona l  du lag lu t idedoses  
co mpa red  to  p laceboa t 18  weeks  in  pa t ien ts  w i th  type  2  d iabe tes  me l l i tus  on  me t fo rm in  
mono the rapy.   
App ro va l  Da te :  [ADDRESS_614398] le c t ron i ca l l y  s igned  and  app ro vedby  L i l ly  on  da te  p rov ided  
be low .
H9X-MC-GBGJ Statistical Analysis Plan Version 1 Page 2
LY21892652.Table of Contents
1. Statistical Analysis Plan:  H9X -MC-GBGJ: A Phase 2, Double -
Blind, Pl acebo -Controlled, 18- Week Trial o f Investi gational 
Dulaglut ide Doses versus Placebo in Patients with Ty pe 2 Di abetes 
on Metformin Monotherapy ................................................................................................ 1
2. Table of Contents ................................................................................................................ 2
3. Revisio n History ................................................................................................................. 8
4. Study  Objectives and Endpoints .......................................................................................... 9
5. Study  Design ..................................................................................................................... 12
5.1. Summary  of Study  Design ............................................................................................ 12
5.2. Determinat ion of Sample Size ...................................................................................... 13
5.3. Method of Assignment to Treatment ............................................................................ 13
6. A Pri ori Stati stical Methods .............................................................................................. 15
6.1. General Considerations ................................................................................................ 15
6.2. Adjustments for Covari ates.......................................................................................... 17
6.3. Handling of Dropouts or Missing Data ......................................................................... 17
6.4. Multicenter Studi es...................................................................................................... 18
6.5. Multiple Com parisons/Mult iplicit y............................................................................... 18
6.6. Patient Popul ation........................................................................................................ 18
6.7. Patient Disposi tion....................................................................................................... 19
6.8. Patient Characteri stics.................................................................................................. 19
6.9. Treatment Compliance .................................................................................................20
6.10. Concomitant Therapy ................................................................................................... 20
6.11. Efficacy Analyses ........................................................................................................ 21
6.11.1. Primary Outcome and Methodology ..................................................................... 21
6.11.2. Addit ional Analyses of the Primary  Outcome ....................................................... 21
[IP_ADDRESS]. MMRM in different populat ions..................................................................... 21
[IP_ADDRESS]. Missing data imputation .................................................................................. 21
[IP_ADDRESS]. Bayesian Analyses For Exploratory Object ives............................................... 21
6.11.3. Secondary  Efficacy  Analyses ............................................................................... 22
[IP_ADDRESS]. The Primary  Analyses for Secondary  Efficacy Endpoints ............................... 22
[IP_ADDRESS]. Supporting Analyses For Secondary  Efficacy Endpoints .................................23
[IP_ADDRESS]. Bayesian Analyses For Exploratory Object ives............................................... 23
6.12. Pharmacokinet ic/Pharmacodynamic (PK/PD) Methods ................................................ [ADDRESS_614399] ....................................................................... 25
[IP_ADDRESS]. Hypoglycemic Epi[INVESTIGATOR_1841] ................................................................................. 25
[IP_ADDRESS]. Severe, Persistent Hy perglycemia ................................................................... 27
[IP_ADDRESS]. Pancreat itis..................................................................................................... 27
[IP_ADDRESS]. C-cell hyperplasia and C -cell Neopl asms ........................................................ 28
[IP_ADDRESS]. Allergic/Hypersensit ivity Reactions ................................................................ 28
[IP_ADDRESS]. Supraventricular Arrhyt hmias and Cardiac Conduction 
Disorders ........................................................................................................ 28
6.13.5. Gastrointestinal Safet y......................................................................................... 28
6.13.6. Treatment of Overdose ......................................................................................... 29
6.13.7. Cardi ovascular Safet y.......................................................................................... 29
[IP_ADDRESS]. Cardi ovascular Events .................................................................................... 29
[IP_ADDRESS]. Electrocardiograms ......................................................................................... 29
[IP_ADDRESS]. Vital Signs...................................................................................................... 31
6.13.8 .Renal Safet y......................................................................................................... 32
6.13.9. Immunogenicit y................................................................................................... 33
6.13.10. Clinical Laboratory  Evaluat ion............................................................................. 33
6.14. Subgroup Analyses ....................................................................................................... 33
6.15. Important Protocol Deviat ions...................................................................................... 34
6.16. Interim Analyses and Assessment Committee .............................................................. 35
6.16.1. Assessment Committee ........................................................................................ 35
6.16.2. Interim Analyses .................................................................................................. 35
[IP_ADDRESS]. Timing of the Interim Analysis ....................................................................... 35
[IP_ADDRESS]. Evaluat ion Cri teria.......................................................................................... 35
6.17. Planned Exploratory Analyses ...................................................................................... 36
6.18. Annual Report Analyses ............................................................................................... 36
6.19. Clinical Trial Registry  Analyses ................................................................................... 37
7. Unblinding Plan ................................................................................................................ 38
7.1. Operati onal Procedures ................................................................................................ 38
7.2. Site Level Unblinding .................................................................................................. 39
7.3. Trial Level  Safety  Reviews .......................................................................................... 40
7.4. Assessment Committee Reports ................................................................................... 40
7.4.1. Safety Only Reports ............................................................................................. 41
7.4.2. Efficacy/Safet y Interim  Report ............................................................................. 41
[IP_ADDRESS]. Model  Development ....................................................................................... 41
[IP_ADDRESS]. Reports Delivery............................................................................................. [ADDRESS_614400] of A ppendices
Appendix Page
Appendix 1. Analysis Windows for the Selected Parameters .............................................. 45
H9X-MC-GBGJ Statistical Analysis Plan Version 1 Page 8
LY21892653.Revision History
Statistical analysis plan ( SAP)Versi on 1 was approved prior to unblinding (or the first visit 
when a subject receives study  drug or any  other protocol intervent ion if the clinical trial is open -
label).
H9X-MC-GBGJ Statistical Analysis Plan Version 1 Page 9
LY21892654.Study  Objectives and Endpoints
Table GBGJ. 1shows the objectives and endpo ints of the study .
Table GBGJ. 1. Objectives and Endpoints
Objectives Endpoints
Primary
To demonstrate that once weekly dulaglutide (4.5 mg, 
3.0 mg, 1.5 mg) is superior to placebo in HbA1c 
reductio n at 18 weeks in patients with T2D on 
concomitant metformin monotherapy.The change in HbA1c from baseline
Secondary
Efficacy
To compare each dulaglutide arm (4.5 mg, 
3.0mg, 1.5 mg) to the placebo arm at 18 weeks 
for secondary efficacy parametersProportio n of patients achieving HbA1c target 
of <7.0% 
The change in fasting serum glucose (FSG; 
central laboratory) from baseline
The change in body weight from baseline
Safety
To compare each dulaglutide arm (4.5 mg, 
3.0mg, 1.5 mg) to the placebo arm for selected 
safety parameters at 18 weeksTreatment -emergent adverse events (TEAEs) 
and serious adverse events (SAEs)
Discontinuation of study drug due to adverse 
events ( AEs)
Incidence and rate of hypoglycemia (severe, 
total, documented symptomatic, and nocturnal)
Pharmacokinetics and Pharmacodynamics
To characterize the pharmacokinetics (PK) of 
dulaglutide and establish the relationships 
between dose/ exposure and key safety and 
efficacy measuresPK parameters (eg, Cmax, AUC)
Pharmacodynamic evaluations will include 
HbA1c, FSG, body weight , QTcF interval, and 
heart rate
Tertiary/Exploratory
Efficacy
To compare each dulaglutide arm (4.5 mg, 
3.0mg, 1.5 mg) to the placebo arm for 
additional efficacy measures at 18 weeksProportio nof patients achieving HbA1c target 
≤6.5%
The change in 6-point self-monitored plasma 
glucose ( SMPG )profile s from baseline
The change in fasting plasma glucagon from 
baseline
The change from baseline in insulin resistance 
(HOMA -
IR) and -cell function (HOMA -%B) 
as measured by [CONTACT_478697]2 Method (Caumo et 
al. 2006) 
H9X-MC-GBGJ Statistical Analysis Plan Version 1 Page 10
LY2189265Objectives and Endpoints
Objectives Endpoints
Tertiary/Exploratory (continued)
Efficacy
To compare the investigational dose dulaglutide
arms (4.5 mg and 3.0 mg) to the 1.5 mg arm for 
efficacy measures at 18 weeksChange f rom baseline in HbA1c
Proportio nof patients achieving HbA1c target
<7.0% or ≤6.5% 
The c hange in FSG (by [CONTACT_12115]) from 
baseline
The c hange in body weight from baseline
The change in 6-point SMPG profile s from 
baseline
The change in fasting plasma glucagon from 
baseline
The c hange in HOMA -IRand HOMA -%B
from baseline
Safety
To compare the investigational dose dulaglutide
arms (4.5 mg and 3.0 mg) to the placebo arm 
for additional safety measures at 18 weeksSelected gastrointestinal tolerability AEs
(nausea, vomiting, and diarrhea)
Pancreatic safety assessed by [CONTACT_478698]
CV safety assessed by [CONTACT_478699]
Thyroid-related safety assessed by [CONTACT_478700]
Vital signs (PR , BP)
ECG (HR, QTcF, supraventricular arrhythmias 
and cardiac conduction abnormalitie s)
Immune system -related safety, including the 
incidence of dulaglutide antidrug antibodies 
(ADA) and the incidence of allergic and 
hypersensitivity reactions
Injection site reactions
Incidence of rescue therapy initiation due to 
severe ,persistent hypergl ycemia
To compare the investigational dose dulaglutide
arms (4.5 mg and 3.0 mg) to the 1.5 mg arm for 
safety measures at 18 weeksTEAEs and SAEs
Discontinuation of study drug due to AEs
Incidence and rate of hypoglycemia (severe, 
total, documented symptomatic, and nocturnal)
Selected gastrointestinal tolerability AEs 
(nausea, vomiting, and diarrhea)
Pancreatic safety assessed by [CONTACT_478698]
CV safety assessed by [CONTACT_478701] r CV 
events
H9X-MC-GBGJ Statistical Analysis Plan Version 1 Page 11
LY2189265Objectives and Endpoints 
Objectives Endpoints
Tertiary/Exploratory (concluded) Thyroid-related safety assessed by [CONTACT_478700]
Vital signs (PR, BP )
ECG parameters (HR, QTcF , supraventricular 
arrhy thmias and cardiac conduction 
abnormalities )
Immune system -related safety, including the 
incidence of dulaglutide ADA and the 
incidence of allergic and hypersensitivity 
reactions
Injection site reactions
Incidence of rescue therapy initiation due to 
severe, persisten t hyperglycemia
Safety
To compare the titration algorithms 
(Algorithm 1 vs. Algorithm 2) within the 
investigational dose dulaglutide arms (4.5 mg 
and 3.0 mg) and across the investigational dose 
arms versus dulaglutide 1.5 mg and placebo at 
6 and 18 weeksIncidence of selected GI AEs (nausea, 
vomiting, and diarrhea)
Vital signs (PR, BP)
Abbreviations: ADA = antidrug antibodies; AE = adverse event; AUC = area under concentration -time curve; BP = 
blood pressure; Cmax = maximum concentration; CV = cardiovascular; ECG = electrocardiogram; FSG = fasting 
serum glucose; GI = gastrointestinal; HbA1c = hemoglobin A1c; HOMA = Homeostasis Model Assessment; HR 
= heart rate; PR = pulse rate; QTcF = Fridericia’s corrected QT inte rval; T2D = type 2 diabetes mellitus ; SAEs = 
serious advers eevents; SMPG = self -monito red plasma glucose ; TEAS = treatment emergent adverse events .
H9X-MC-GBGJ Statistical Analysis Plan Version 1 Page 12
LY21892655.Study  Design
5.1. Summary of Study Design
Study  H9X -MC-GBGJ (GBGJ) is a rando mized, mult icenter, placebo -controlled, double -blind 
Phase [ADDRESS_614401] of 2 dulaglut idedose 
titration algori thms on gastrointestinal ( GI)tolerabili ty with invest igational doses to guide design 
of the definit ive algorithm to be evaluated in Phase 3 trials. The primary objective of this trial is 
to show superiorit y of the 3 dulagluti dedoses (4.5 m g, 3.0 mg, 1.5 m g) to pl acebo in change in
hemoglo bin A1c (HbA1c )at 18 weeks .
During the trial, an unblinded internal assessment committee (AC) will review data on safet y and
tolerabilit y in study  parti cipants according to a prespecified schedule in order to assure the safety
of rando mized pat ients.  An efficacy/safety  interim analysis will be conducted after 
approximately  [ADDRESS_614402] of 3 peri ods: an approximately 2- week l ead-inperiod, followed by [CONTACT_1629] 18-
week treatm ent peri od, and a [ADDRESS_614403] 4 weeks of the titration
phase, and 2 injections per week in the remainder of the titration phase.
b During the maintenance phase, the assigned dose will require 3 injections .
Figure GBGJ .1. Illustration of study design for Clinical Protocol H9X -MC-GBGJ.
5.2. Determination of Sample Size
Assuming a screen failure rate of 30%, approximately 429 patients will need to be screened to
attain approximately 300 patients rando mized to the 4 treatment a rms in a 1:1:1:[ADDRESS_614404] acebo weekly (~75 patients per arm). For the
investigat ional dulaglut idedose arms (4.5 mg and 3.0 mg), approximately 38 patients will be
assigned to each titration algorithm (Algorithms 1 and 2). Assuming a 20% dropout, this will
resul t in approximately  60 pati ents per arm  and 30 patients per algorithm (in each of the
investigat ional-dose dulaglut idearms) com pleting the study.
The aforem entioned sample size provides ≥90% power to dem onstrate superi ority for the
dulaglut idedoses (4.5 m g, 3.0 m g, and 1.5 m g) to pl acebo wi th respect to HbA1c change fro m
baseline to [ADDRESS_614405] difference of - 1% HbA1c for each
dulaglut idedose versus placebo, and a standar d deviat ion (SD) of 1.2% with a 2- sided alpha of
0.05.
5.3. Method of Assignment to Treatment
Patients who m eet all cri teria for enrollment will be randomized to oneof the study  treatm ent 
armsat Visi t 3. Assignment to treatment arms will be determined by a co mputer -generated 
rando msequence using an Interactive Web Response Sy stem  (IWRS ). The IWRS will be used 

H9X-MC-GBGJ Statistical Analysis Plan Version [ADDRESS_614406] cartons by [CONTACT_45342] a confirmat ion number found on 
the label into the IWRS.
Block randomizat ion will be used at the coun try level. Patients will be rando mized in a 1:1:1:1
ratio (dulaglutide 4.5 mg, dulaglut ide3.0 mg, dulaglutide1.5 m g, placebo). Within the
dulaglut ide4.5 m g and 3.0 m g arms, pati ents will  be randomly assigned (1:1) to Algorithm 1 or
Algori thm 2. Rando mizat ion will be stratified by [CONTACT_13505]1c (<8%, ≥ 8%).
H9X-MC-GBGJ Statistical Analysis Plan Version [ADDRESS_614407] ical analysis plan ( SAP)or the clinical study  report (CSR). Addit ional 
exploratory  analyses of the data m ay be conducted as deemed appropriate without further 
changes made to the protocol or SAP even after the datalock .
Countries wi th fewer than [ADDRESS_614408] ical analyses. Pooled
country  will be em ployed for all  formal statistical  model-based analyses as a bl ock f actor unl ess 
otherwi se denoted .
Unless otherwise specified, all tests of treatment effects will be conducted at a 2 -sided alpha
level of 0.05, and confidence intervals (CIs) will be calculated at 95%, [ADDRESS_614409] nonmissing measurement taken prior to this visit will be used
for the baseline measurement. The efficacy  measure for the primary  analysis is defined as the
change from baseline in HbA1c to Week 18 (Visit 12).
For all statist ical analyses, missing data will be treated as missing at random unless otherwi se 
specified ; therefore, no imputation is needed unless otherwise stated.
The treatment groups ment ioned in this document are based on the rando mized treatment groups : 
dulaglut ide4.5 mg, dulaglut ide3.0 m g, dulaglutide 1.5 m g, placebo .For the purposes of tables, 
figures, the treatment groups will be: Dula 4.5, Dula 3.0, Dula 1.5, and Placebo. For data 
listings, the treatment groups will be presented as Placebo, Dula 1.5, Dula 3.0/A1 represent ing 
dulaglut ide3.0 m g/algori thm 1, Dul a 3.0/A2 representing dulaglut ide3.0 m g/algori thm 2, Dul a 
4.5/A1 represent ing dulagluti de 4.5 mg/algori thm 1, Dul a 4.5/A2 represent ingdulaglut ide
4.5mg/algorithm 2.
Incidence of nausea, vo miting, and diarrhea, vital signs ( pulse rate, blood pressure [ PR, BP ]), 
electrocardi ogram  (ECG )variables (heart rate [ HR], PR interval , and Fridericia’s corrected QT 
interval [QTcF]), and pancreat ic enzyme (amylase and lipase) will be summarized by[CONTACT_478702], and by [CONTACT_478703], and 
by [CONTACT_478704].
Placebo will  serve as the reference treatment for each dulaglu tidedose, while dulaglut ide1.[ADDRESS_614410] ( Appendix 1 , Table APP1.1)not the actual visit number reported by [CONTACT_39722]. For the other m easures, the actual scheduled visit reported by  [CONTACT_478705].
Amixed -model repeated measure s(MMRM) analysis will be used to analyze cont inuous 
longitudinal variables.  In th is model, restri cted m aximum  likelihood will be used to obtain 
model estimates wi th Kenward -Roger (KR) option to estimate deno minator degrees of freedo m.
The corresponding baseline value will be used as a covariate, and thestratificat ion factors 
(pooled country , HbA1c strata [ screening HbA1c at Visit 1: <8.0%, ≥8.0%]), treatm ent 
(dulagluti de4.5 mg, dulaglut ide3.0 mg, dulaglut ide1.5 m g, placebo ), visit, and treatment -by-
visit interaction will be fixed effects.  For HbA1c change fro m baseline analysis or HbA1c target 
analysis ,  HbA1c strata will be replaced wi th continuous baseline HbA1c as a covariate fro m the 
aforem entioned model.  An unstructured covariance structure will be used to model the within -
patient errors. If this model fails to converge, the following covariance structures will be tested 
in order:
toeplitz with heterogeneit y
autoregressive with heterogeneit y, by [CONTACT_765]
compound symmetry  with heterogeneous variances by  [CONTACT_765] 
toeplitz
autoregressive
compound symmetry  without heterogeneous varian ces, by  [CONTACT_765]
compound symmetry
The first covariance structure that converges will be used.
The analysis of covaria nce(ANCOVA) as a sensit ivity analysis for the primary  and secondary  
continuous efficacy  endpoints using the last observation carried forward (LOCF) described in 
Secti on 10.3.1 of the protocol H9X- MC-GBGJ( a) will  not be used for analyses of secondary  
continuous efficacy  endpoints as the analysis was shown to produce bias edresul ts (Lachin 2016)
with little inferen tialvalue. 
For continuous l aboratory  measurements for safety, an analysis o f variance (ANOVA) on ranks 
will beused with treatm ent as a fixed effect.
For all continuous measures, summary  statistics will  include number of patients , mean, SD, 
median, minimum, and maximum for both the ac tual and change from baseline values at each 
scheduled visit for each treatment unless otherwise specified .  Least -squares mean (LS mean) 
and standard errors (SEs) derived fro m the model will also be displayed for the change from 
baseline values at each sc heduled visit for each treatment .  Treatm ent com parisons will be 
displayed showing the treatment difference LS mean and the 95% CIs between each dose and 
placebo, and between each invest igational dulaglutide dose and 1.5 mg at the same visit , along 
with the corresponding p-values.
H9X-MC-GBGJ Statistical Analysis Plan Version 1 Page 17
LY2189265Summary  statistics for categorical measures will incl ude number of subjects and percentages.
The perce ntage of patients achieving target HbA1c <7.0% at Week [ADDRESS_614411] ic regressio n with repeated m easurem ents with treatm ent, vi sit, treatm ent-by-
visit interaction, and baseline HbA1c -by-visit interaction as fixed effects and baseline HbA1c as 
a covari ate.  For the analysis o f other categorical measures, Fisher’s exact test will be used for 
treatm ent com parisons, unless 80% of cells have an expected value of at least 5, in which case 
the Chi-square test will be used unless otherwi se stated .Unless otherwise stated, categorical 
variables will be summarized by  [CONTACT_19462], the number of patients andpercentages for each 
treatm ent group at each visit. 
Imputed data m ay be applied in m odel-based data analysis, but will not be used in data list ing.
The l atter will only  present the non -imputed raw data including sitereported scheduled, site
reported unscheduled, or early terminat ion visit data; however, only  scheduled visi ts for the
measure of interest ( Appendix 1 ,Table APP1.1 ) will be included in the summary  table and
statist ical inference unless otherwi se stated .
Addit ional analyses m ay be performed even after datalock if deemed needed.
All statistical analyses will be conducted with Statistical Analysis System  (SAS)Versi on 9.4 ®or 
higher unless otherwise stated.
6.2. Adjustments for Covariates
The study  is stratified by [CONTACT_28007]1c with country as a block factor ; therefore, both 
stratificat ion factor swill be fitted inthe corresponding statist ical model as fixed effect sfor the 
non-HbA1c measurements unless otherwise stated .  For HbA1c analysis, the strata of baseline 
HbA1c will be replaced with the covariate of baseline HbA1c. For other continuous variables 
other than so me safet y laboratory  measures, a corresponding baseline measure will be added as a 
covari ate.
6.3. Handling of Dropouts or Missing Data
Missing data will be imputed as a sensit ivity analysis for the primary  and key  secondary  
continuous endpo intsusing a tippi[INVESTIGATOR_67659], and copy  reference approach.  The 
reference is from those patients on the same treatment who received rescue medicat ion and/or 
stopped study  medicat ion, but had the measurement for the corresponding endp oints.
For HbA1c target of <7.0 % and ≤6.5% , those who have missing data at Week 18 (Visit 12) or 
who receive rescue therapy  prior to the Week [ADDRESS_614412] (LOCF) to impute the missi ng endpoint data will be used for 
the non-longitudinal continuous variables such as [ADDRESS_614413] asma glucose 
(SMPG ),Hom eostasis Model Assessment (HOMA -IR), and HOMA -%B, c-peptide, fasting 
insulin, and the selected safet y laboratory measures.
H9X-MC-GBGJ Statistical Analysis Plan Version 1 Page 18
LY2189265Any missing co mponent of date and/or time will beimputed f ollowing Lilly or dulaglut ide
compound level  standards. For example , themissing day or month couldbe imputed with the 
first day  of the m onth, or first m onth of the year.
If the first dosing date/ time is missing, the non -missing rando mizat ion date will be used t o 
impute the first dosing date and the time will be placed with [ADDRESS_614414] 
after datal ock. 
6.5. Multiple Comparisons/Multiplicity
This is an exploratory  Phase 2 study; thus, multiplicity adjust ment will not be performed .
6.6. Patient Population
Five patient populat ions are defined for the analyses in this study  with detailed informat ionlisted 
in Table GBGJ .2.  Unless otherwise specified, list ings will include all rando mized pat ients. 
Efficacy and safet y analyses will be conducted in the intent -to-treat (ITT) population. The 
prima ry efficacy  measure (change fro m baseline in HbA1c) will also be evaluated in the per 
protocol  (PP) population and Co mpleter set (CS) populat ion
.
In all efficacy  and hypoglycemia analyses, all data after rescue therapy  will be censored unless 
otherwi se sta ted.
Analyses of safet y parameters, except for hy poglycemia events, will be conducted in the ITT
popul ation including the post -rescue therapy data.
H9X-MC-GBGJ Statistical Analysis Plan Version [ADDRESS_614415] 1 dose of study medication 
for an assigned treatment arm
All randomized population All patients who are randomized 
Per protocol All ITT patients who meet all of the following criteria:
Have no important protocol deviation that could impact the assessment 
of the primary endpoint ; the list of specific criteria is provided in 
Section 6.15
At least 75% compliant with study drug administration
Complete the treatment period (18 weeks) 
Have a value of the primary efficacy measure at 18 weeks
Note: the final criteria will be documented in electronic Trial Master 
File(eTMF) .  
Completer set All ITT patients who complete 18 weeks of study drug tre atment without rescue 
therapy
Abbreviation:  HbA1c = hemoglobin A1c ; ITT = intent to treat .
6.7. Patient Disposition
The reasons for pati ent di scontinuat ions from study medicat ionand fro m the study will be 
summarized for all randomized subjects by [CONTACT_478706] , by [CONTACT_765] , and overall .An 
additional report will be provi de to provi de combined disposit ion report for early discont inuat ion 
of study  drug and early  discontinuati on of  study , by [CONTACT_765], cum ulative and overall. The l atter 
report i s need to accoun t for pati ents who perm anent ly discont inue study  drug but continued in 
the trial, as allowed by  [CONTACT_23643] .
The p -value to test the overall treatment effect among all rando mized treatments and the p
-value 
will be presented using Fishe r’s exact test or Chi -square test detailed in Sect ion 6.1.
Kaplan -Meier curves by  [CONTACT_478707] l be 
presented. The l og-rank p -value will be presented.
In addit ion, all entered patients will be summarized including, but not limited to, the total
number of patients screened (entered) andthe number of patients excluded due to screen failure .
Patient disposit ion will be listed for all rando mized population.
6.8. Patient Ch aracteristics
Dem ographic and baseline clinical characteristics will be summarized by  [CONTACT_478708] 6.1. For con tinuous measures, summary statist ics will include 
sample size, mean, median, maximum, minimum, and SDalong wi th the ANOVA p -value to test 
for difference amo ng all randomized treatm ent groups.For categorical measures, summary 
statist ics will include sample size, the number and percent age of patients for each category with 
Fisher’s or Chi -square p- value . In the summary  report , each algorithm arm will be included.
H9X-MC-GBGJ Statistical Analysis Plan Version [ADDRESS_614416] 75% of therequi red inject ions for 
the prespeci fiedtime intervals : titration phase from the firstdose to the sixth dose, and every 
4 weeks thereafter: from the seventh dose to the [ADDRESS_614417] 75% 
compliant with invest igational product across the treatment period. Compliance source data is 
from the site reported case report form ( CRF)data.
Com pliance will  be summarized using ITT popul ation by [CONTACT_478709] , and overall.  Listings will also be produced from all rando mized populat ion
.
6.10. Concomitant Therapy
The prespecified conco mitant medicat ions of interest will be summarized (detailed in 
Secti on6.1) by [CONTACT_478710],for the
ITT populat ion.In addit ion, antihyperglycemia medicat ions will be also summarized at 
screening and for the last 3 months prior to study  enro llment by [CONTACT_478711].   The concomitant therapi[INVESTIGATOR_478689] h Organization (WHO)
DRUG di ctionary in the clinical  trial database and will be further classified using Anatomic -
Therapeut ic-Chemical (ATC) codes for reporting purposes.
The agents of interest for the summary  report include the following group sof medicat ion:
anthihyperglycemia agents
obackground metformin therapy
oagents used for short term therapy  for acute condition
orescue therapy (only applicable for after randomization)
oagents used for other reasons
weight loss medicat ions
systemic glucocortico ids
antihypertensive agents
lipid l owering agents
anticoagulant agents
anti-inflammatory agents
cardi actherapy
Concomitant therapy  will be listed for the all -randomized popul ation.
H9X-MC-GBGJ Statistical Analysis Plan Version 1 Page 21
LY21892656.11. Efficacy Analyses
6.11.1. Primary Outcome and Methodology
The primary  analysis for th e primary outcome , change fro m baseline in HbA1c at Week 18 
(Visit 12) , will empl oy MMRM described in Section 6.1in ITT populat ion by [CONTACT_478712].
The report from this analysis includes LSmeans and corresponding 95% CI sfor each 
rando mized treatment at each scheduled visit, and the difference in LS means, correspondi ng 
95% CI al ong wi th p-value compare dto placebo and to dulaglutide1.5 m g at the same visit.
6.11.2. Additional Analyses of the Primary Outcome
[IP_ADDRESS]. MMRM in different po pulations
Different populat ions including ITT regardless of rescue therapy  or adherence to study  drug, PP , 
CS popul ation will be evaluated separately  using the sam e model as described in Sect ion 6.1  
The goal for these analyses is to assess the robustness of the primary outcome.
The output will be generate d as that listed in Section 6.11.1.   
[IP_ADDRESS]. Missing data imputation
If the conclusio ns differ among the four po pulations listed in Section 6.11.1 and Section [IP_ADDRESS] , 
additional analyses m ay be further explored using selected pattern mixture m odels for missing 
data ( Kenward and Rosenkranz 2011) in the ITT popul ationregardl ess of rescue therapy or 
compliance to the study  treatment .In this case, i mputed [ADDRESS_614418] to assess how severe departures from 
missing at random (MAR) need to be in order to overturn conclusions fro m the primary analysis .  
In the dulagluti dearms,the imputed values will be replaced by [CONTACT_478713] a shift 
param eter beginning fro m 0 with the increment of 0.05. Each value of the shift parameter will 
be tested sequentially unt il the value is reached at wh ich the conclusio n from the MMRM 
analysis is reversed. That value is the tippi[INVESTIGATOR_478690].  If implausible departures fro m MAR are 
requi redto change the resu lts from statisti cally significan t(p≤0.05) to not statistically significan t
(p>0.05), the results will be said to be robust to the departure from MAR assumpt ion and provide 
more confiden cein the results obtained based on statist ical methods wi th the MAR assumpt ions.
[IP_ADDRESS]. Bayesian Analyses For Exploratory Objectives
A Bayesian integrated 2 -component predi ction (ITP) model (Fu and Manner 2010) will be fitted 
for the primary  endpoint separately in ITT populat ion by [CONTACT_478714], 
H9X-MC-GBGJ Statistical Analysis Plan Version 1 Page 22
LY2189265and in ITT popul ationincluding all available data regardless of rescue medicat ion or adherence 
to the study  drug . Non -informat ivepriors will  be used in this m odel.In addit ion, the informative 
priors from  the posteri or forplacebo and posterior for dulaglut ide1.5 m g obtained from Stud y
H9X -MC-GBCF ( GBCF )and Study H9X -MC-GBDE (GBDE) will be evaluated in this model to 
check the robustness of the analysis.
)11( ) ) ( (18
      
ii
kt k
ijt ij ij i ijteeB B S Y  
Prior informat ion:θi, α~N (0, 3); Sij, ε ijk, ~uniform ( 0.01, 3); k i~uniform ( - 1, 1)where Y ijt 
represents HbA1c change from baseline fro m dose i , subject j  at time t. Parameter θiis the 
predi cted drug effect of dose i at 18- week therapy . The parameter S ij is a rando mbetween -
subject SD, and εijtis the within subject SD. The Bijis baseline HbA1c for subject j at dose i and 
_
Bis the overall arithmet ic mean baseline HbA1c from all subjects. kiis the parameter to 
represent how fast to reach the effect for dose i at Week 18.
Probabilit ies based on posterior distribut ions of the parameter of interest : change fro m baseline 
to Week 18, and Week 26 will be generated fro m this mod el using [ZIP_CODE] MCMC samples with 
thin=10 and burn -in=[ZIP_CODE] :
                       pr(Δ i-Δdula1.5mg < thresho ld)
                       istands for dulaglut ide3.0 m g or 4.5 m g.
            The thresho ld of -.15, -.2, and -.3% will be used, separately.
If this model fails to converge, an alternat ive Bayesian model will be fitted:
                   
] , [ ] , [ ) ] , [ ( ] , [)],, [ ( ~
0 t i T t i B j i B t i ut i MVN yijt
    
 
    
Where β [i,t] is the effect for dose i at time t.  Ωis the variance -covariance matrix.
The pri ors for each parameters are :  α ~ N( 0,3), β[i,t]~ N (0,3) , Ω~wishart(t, t -demensio n 
Ident itiy matrix ).
The probabilit y for Week 26 will be assumed to be the same as Week 18 from this model .
6.11.3. Secondary Efficacy Analyses
[IP_ADDRESS]. The Primary Analyses for Se condary Efficacy Endpoints
The ITT population by [CONTACT_478715]-rescue data is the analysis populat ion for secondary  
efficacy endpoints. Data for se condary endpo ints will be summarized as described in 
Secti on6.1. The MMRM described in Sect ion 6.1will be used to analyze each secondary  
H9X-MC-GBGJ Statistical Analysis Plan Version 1 Page 23
LY2189265continuous efficacy  endpoint : change fro m baseline in FSG and body  weight . The result will be 
reported as detailed in Section 6.11.1 .
The proporti on of patients achieving HbA1c target <7.0% will be analyzed using repeated
measures logist ic regressio nmixed model described in Sect ion 6.1as the primary analysis . 
Pooled country , treatm ent, vi sit, treatm ent-by-visit interaction will be fitted as fixed effects, 
baseline HbA1c as a covari ate. This m odel will be fitted to leverage all available data without 
imputati on.
[IP_ADDRESS]. Supporting Analyses For Secondary Efficacy Endpoints
As a sensit ivity analysis for proportion of pat ients on HbA1c targets, a logistic regression model 
will be fitted with pool ed country  and treatm ent as fixed effect, baseline HbA1c as a covariate to 
analyze the endpo int data . Prior to this analysis, the missing data or the patients rescued up to 
Week 18 will be imputed as not achieving HbA1c target.
The analyses liste d in Secti on [IP_ADDRESS] will be repeated for the ITT populat ion without censoring 
the post rescue data as a sensit ivity analysis to FSG and body  weight change from  baseline .
[IP_ADDRESS]. Bayesian Analyses For Exploratory Objectives
A similar Bayesian ITP model listed in Sect ion [IP_ADDRESS] will be fitted to analyze body weight 
change from baseline as a supportive analysis by [CONTACT_478716] θi, 
α~N(0,100).
Probabilit ies based on posterior distribut ions of the parameter of interest : change fro m baseline 
in body  weight at Week 18, and Week 26 will be generated fro m this m odel using [ZIP_CODE] MCMC 
samples with thin=10 and burn -in=[ZIP_CODE] :
                       pr(Δ i-Δdula1.5mg < thresho ld) 
                       istands for dulaglut ide3.0 m g or 4.5 m g.
The thresho ld for this analysis will be-1 kg and -
2 kg.
If this model doesn’t converge, the similar alternativ e Bayesian m odel in Sect ion [IP_ADDRESS] will be 
adopted wi th the priors: α, β[i,t]~N(0,100).
The probabilit y for Week [ADDRESS_614419] ion [IP_ADDRESS] .
6.12. Pharmacokinetic/Pharmacodynamic (PK/PD) Methods
All PK/PD analyses will be performed by [CONTACT_478717] a separate
analysis plan.
6.13. Safety Analyses
The safet y analyses will include adverse events ( AEs), serious adverse events ( SAEs ), AEs of 
special interest (AESIs ), and treatm ent em ergent adverse events ( TEAEs ), safet y laboratory  
H9X-MC-GBGJ Statistical Analysis Plan Version [ADDRESS_614420] asms, 
allergic/hypersensit ivity react ions, supraventricular arrhy thmias and cardiac conduct ion 
disorders .
An AE will be cod ed using the Medical Dict ionary for Regulatory  Activities (MedDRA).
TEAEs are defined aspostbaseline events that are new events or preexisting condit ions that 
worsened in severit y after randomizat ionusing MedDRA l ow level  term  (LLT).   The maximum
severi ty level for baseline and post baseline for each same LLT term will be used as a cri terionto 
determine TEAEs. If an AE occurs on the same date as the first dosing date with missing event 
occurring time, that event will be counted as post baseline event.
Unless otherwise specified, the ITT populat ion will be used for analyses of safet y measures , and 
all rando mized populat ion for data list ing.
6.13.1. Extent of Exposure
Treatment exposure is defined as the time from when the patient took his/her first dose until th e
last dosing date. If that first dosing date is missing, it will be imputed with the date of 
rando mizat ion. If the last dosing date i s missing, i t will be imputed with the date thepatient 
discontinued treatm ent or com pleted the treatment period, whi chever is earlier.
Exposure will be calculated for each patient. It will be summarized for ITT popul ation by 
[CONTACT_478718], SD, minimum, maximum, the firstquartile and the thirdquartile. The 
mean exposure duration in days among treatment groups wi ll be co mpared with ANOVA model 
using treatm ent as a fixed effect.  The p -value to compare the overall randomized treatm ent 
effect will be presented .  The total pat ient-years of study  drug exposure will be added at the end 
of the summary .Durati on of  expo sure was categorized into the fo llowing groups: ≤28 day s, >28 
to ≤42 days, >42 to ≤56 days, >56 to ≤70days, > 70to ≤98 days, >98 and 126 day s, >[ADDRESS_614421]’s 
detailed dose informat ion at each post dose week (first dosing week will be coded as week 1 ) 
willbe calculated based on the CRF sourced fro m the study  drug administration log . For the 
maintena nce phase, the dose informat ion will use the package informat ion for the missed 
inject ion(s). For the titration phase, the package informat ion is not needed . For the first four 
weeks, missed inject ion means the entire dose is missed. For each of the last [ADDRESS_614422] ions means full dose, half dose, or no dose injected, respectively.  
This dose informat ion along with the actual dosing date/time will be used for patient narratives, 
and PK analysis.   The actual dosing in formation calculated in this section will  be summarized by  
[CONTACT_478719] .The exposure data will be listed for ITT popul ation.
6.13.2. Adverse Events
Unless otherwise specified, AEs will be reported using the MedDRA system organ class (SOC) 
andpreferred term  (PT). Selected AEs may be reported using MedDRA high -level term s (HLT) , 
in addition to the SOC and PT, forconsisten cywithother dulagluti destudies .Treatment -
H9X-MC-GBGJ Statistical Analysis Plan Version [ADDRESS_614423] dosing.
Summary  statistics will be provided for the following data: m edical history and/or pre -exist ing 
condi tionAEs, TEAEs, SAEs, TEAESIs, and study discont inuat ions due to death or AEs .For 
TEAEs, SAE an d TEAESIs will be reported separately from baseline to the end of the treatment 
period, and to the end of the study including safet y follow-up. The number and proportions of
patients experiencing each corresponding AEs will be reported for each rando mized treatm ent 
group .Chi-square or Fisher’s exact tests will be used to compare the randomized treatm ent 
groups detailed in Sect ion 6.1.
Theincidence of patients with at least one TEAE will be reported, and the proportion of patients
experiencing each reported TEAE will be presented by [CONTACT_6214] (descending order) and by 
[CONTACT_478720] , and also by [CONTACT_167935] (alphabet ical order ) andby [CONTACT_478721] . Theproporti on of  patients experiencing each reported TEAE that are 
assessed as related to the study  disease, study  drug device, or pro cedures will be su mmarized .
Note, drug device is coded as concomitant device. Addit ionally, a summary  of TEAEs by 
[CONTACT_41424] y will be presented descript ively by [CONTACT_478722].
Separate summary  reports will be provi ded for t he number and percentage of pati ents who 
discontinued fro m the study  and for pati ents who discontinue study  treatm ent due to AE or death 
by [CONTACT_478723].  If deemed 
necessary , a Bayesian m odel may be fi tted to eval uate if the probabilit y of the incidence o f 
discontinuat ion due to AEs for any  invest igational dose being ≤10%, ≤15%
.
Listingswill be provi ded for SAE s, TEAE s, and discontinuation sdue to AE or de ath.
Addit ional analyses will be performed for the purpose of fulfilling the clinical trial registry
(CTR) requirements (Section 6.19)
.
6.13.3. Deaths, Ot her Serious Adverse Events, and Other Notable 
Adverse Events
All SAEs will be summarized by  [CONTACT_478724] , and by 
[CONTACT_3592] (descending frequency order within SOC ). Death will be listed including both 
adjudicated and invest igator reported .Patient listings for the patient narrative swill be generated
for further process ing.The cri teria for patient narrative swill be provi ded by [CONTACT_478725].
6.13.4. Adverse Events of Special Inte rest
[IP_ADDRESS]. Hypoglycemic Epi[INVESTIGATOR_478691] . Hypoglycemia will be analyzed as documented symptomatic, 
asymptomat ic, probable, severe, total, and nocturnal hypoglycemia with the defini tion (American
Diabetes Association 2005) below:
H9X-MC-GBGJ Statistical Analysis Plan Version 1 Page 26
LY2189265Documented symptomatic hypoglycemia :any t ime a patient feels that he/she is 
experiencing symptoms and/or signs associated with hy poglycemia, and has a PG 
level of ≤70 mg/dL ( ≤3.9 mmo l/L).
Asymptomatic hypoglycemia : any event not accompanied by  [CONTACT_11017][INVESTIGATOR_82344] s 
of hypoglycemia ,but wi th a measured PG ≤70 mg/dL (≤3.9 mmo l/L).
Probable symptomatic hypoglycemia :an event during which symptoms of 
hypoglycemia are not accompa nied by  a PG determinat ion (but that was 
presum ably caused by a PG concentration ≤70 m g/dL [≤3.9 mmo l/L]).
Severe hypoglycemia : an epi[INVESTIGATOR_478692], gl ucagon, or oth er resuscitative act ions.  These 
epi[INVESTIGATOR_1841] m ay be associ ated wi th sufficient neuroglycopenia to induce seizure or 
coma.  Plasma glucose measurements may not be available during such an event, 
but neurological recovery  attributable to the restoration of PG to normal is 
considere d sufficient evidence that the event was induced by a low PG 
concentration.
Total hypoglycemia: any event of documented symptomat ic, asymptomat ic, 
probable, unspecified, severe hypoglycemia.   Unspecified hypoglycemia is 
defined as an event during which PG ≤ 70 mg/dl (3.9 mmo l/l) but no information 
relative to symptoms of hypoglycemia was recorded.
Nocturnal hypoglycemia :any total hypoglycemic event that occurs between 
bedtime and waking.
A different glucose threshol d of <54 m g/dL (<3 mmo l/l) may also be included in these analyses 
when deemed appropriate.
For each category  of the aforem entioned hypoglyc emia categori es, the incidence will be 
analyzed using the methods for analyses of categorical data described in Sect ion 6.1, by[CONTACT_478726];the rate of hypoglycemic epi[INVESTIGATOR_126150] a generalized 
linear mixed -effects m odel assuming negat ive bino mial distrib ution for hy poglycemic epi[INVESTIGATOR_478693] , treatment, visit, and treatm ent-by
-visit interact ion as fixed effect s and
baseline HbA1c and baseline rate as covariates. The logarithm of days between visits will be 
adjusted as an offset to account fo r possible unequal duration between visits and between 
patients. This model will be implemented using SAS ®procedure GLIMMIX using the log link 
funct ion. The predicted hypoglycemia rate per 1- year by [CONTACT_478727]. An unstructured covariance structure will be used to model the within -patient errors. 
If this analysis fails to converge, the fo llowing covari ance structures will be tested in this order:
compound symmetry , then autoregressive. For r are hypoglycemic epi[INVESTIGATOR_478694], stratified Wilco xon rank sum test will be used to test 1-year corresponding 
hypoglycemia rate between each dula glutidedose and placebo, and between each 2higher dose 
and dulagluti de1.5mg.
A listing of individual hypog lycemic epi[INVESTIGATOR_81082].
H9X-MC-GBGJ Statistical Analysis Plan Version 1 Page 27
LY21892656.13.4.2. Severe, Persistent Hyperglycemia
Summaries (if appropriate ) will be provided for events of severe, persistent hyperglycemia
(Protocol Sect ion [IP_ADDRESS]) resul ting in init iation of rescue therapy by[CONTACT_478728].  
The time to the first rescue therapy  use will be analyzed using PROC LIFETEST to generate 
Kaplan -Meier (KM) curves for each treatment. The summary report swill be only generated if 
more than 3%patients receive rescue intervention .
The patients who experienced severe, persistent hyperglycemia will be listed.
[IP_ADDRESS]. Pancreatitis
Summaries of adjudicated and investigator -reported pancreat ic events will be provided by [CONTACT_478729] .However, the summary report will only be generat ed if more than 3% 
patients have pancreat ic event(s). Determinat ion of investigator -reported events will be through 
the “Acute pancreat itis”Standardized MedDRA Queries (SMQ )anda “Chronic pancreatit is”
Lilly Search Categories ( LSC)of the AE database, while adjudicat ion-confi rmedpancreat itis
will be found f rom adjudicat ion CRF .
The patients developi[INVESTIGATOR_478695] -reported and the 
adjudicated events.
Each pancreat ic enzyme at Week [ADDRESS_614424] -dose value will be 
summarized by  [CONTACT_478730], dul agluti de 3.0 m g/algori thm 1, dul aglut ide 
3.0mg/algorithm 2, dulaglutide 4.5 mg/algorithm 1, dulaglut ide 4.5 mg/algorithm 2, algorithm 1, 
and algorithm 2 in a shift  table using >1 upper limit normal (ULN), and ≥[ADDRESS_614425] separately for 
the ITT populat ion, ITT populat ion with normal baseline, ITT populat ion with baseline value > 
ULN.
A MMRM with pooled country , baseline HbA1c strata, treatm ent, vi sit, and treatment -by-visit 
interact ion as fixed effects will be fitted to analyze each pancreat ic enzyme (p -amylase and 
lipase). In thi s model, the l og transform ed rati o (post fi rst dose m easure/baseline measure) will 
be the response variable and log transform ed baseline meas ure instead of baseline measure will 
be a covariate.   The variance -covari ance structure select ion is detailed in Sect ion 6.1.The 
treatm ent in the model will include placebo , dulaglutide 1.5 mg, dulaglut ide3.0 m g/algorithm 1, 
dulaglut ide3.0 m g/algori thm 2, dulaglut ide4.5 m g/algorithm 1, dulagluti de4.5 m g/algori thm 2.  
The report from this analysis will include :
1)Geom etric LS m eans and corresponding 95% CIs for each rando mized treatment at each 
scheduled visit, and the ratio in geometri c LS means, corresponding 95% CI along with 
p-value compared relative to placebo and to dulaglutide 1.5 m g at the same visit.
2)Geom etric LS m eans and corresponding 95% CIs of pancreatic enzyme for algorithm 1, 
algorithm 2after adj usting for baseline , and the ratio between algori thm 2 and a lgorithm 
1 (using a lgori thm 1 as reference) at Week 6 (Visit  6).  These results won’t be acquired
directly from the MMRM m odel.Rather, they  will be obtained from  the same m odel by 
[CONTACT_478731]
3.0mg and dulaglut ide4.5 m g.
H9X-MC-GBGJ Statistical Analysis Plan Version 1 Page 28
LY21892653)Geom etric LS m eans and corresponding 95% CIs of pancreatic enzyme for dulagluti de
3.0, d
ulaglut ide4.5after adj usting for baseline , and the ratio between each combined 
treatm ent across algorithms and placebo, and the difference between each combined 
treatm ent to Dulaglutide 1.5 at the same Week (Visit):  Week 6 (Visit 6), Week 18 
(Visit 12).  These results will be obtained through the same model by [CONTACT_478732].
4)The ratio ofgeometric LS means and the corresponding 95% CIs along with the p -value 
betwe en each m aintenance visit (Week 18/Visit 12) and the end of titration (Week 6/Visit 
6) wi thin the same treatment including the d
ulaglutide 3.0 m g,and 4.5 m g, and wi thin the 
same algorithm will be presented.  Any result related to combined treatment across 
algorithms and each 
algorithm at Vi sit 6 (Week 6) will  be formed by  [CONTACT_478733].
[IP_ADDRESS]. C-cell hyperplasia and C -cellNeoplasms
Listings of AEs of interest using a LSC will  be provided by [CONTACT_478734] , 
thyroid neopl asms malignant and thy roid disorders , as well as a list ing of biopsy  reports. The 
summary report for these AESIs by  [CONTACT_478735] 3% pati ents with these AESIs.
Calcitonin data will be summarized using an ANCOVA model wit h treatment as a fixed effect 
by [CONTACT_303918]. The response variable will be the rank onthe change fro m baseline .
Calcitonin values will be listed for those pati ents wi th a post first dose serum calcitonin increase 
from (mean of  the screening and baseline measures) ≥ 50% and the absolute value ≥20 pg/ml .
These pat ients will be class ified by [CONTACT_478736] v alues into the following categories: 
≥20 and <25 pg/ml; ≥35and <50 pg/ml; and ≥50 pg/ml. A shift table using these categories will 
be generated ifthe proporti on of  patients with these changes is 3% or more.
[IP_ADDRESS]. Allergic/Hypersensitivity Reactions
Listings of allergic /hypersensit ivity AEs will be generated .If the number of patients with these 
events is 3%or more, then, a summary report will also be generated by [CONTACT_478737] .
A similar summary and list ing will be generated for patie nts wi thinjection site react ions.
[IP_ADDRESS]. Supraventricular Arrhythmias and Cardiac Conduction Disorders
Summaries of theseAESIswill be produced by  [CONTACT_478738] .  The data list ing will be generated.  The qualitat ive ECG data 
including conduction and arrhyt hmia will be summarized by [CONTACT_478739].
6.13.5. Gastrointestinal Safety
Because certain GI AEs, including nausea, vo miting, and di arrhea, are among the most commo n 
events reported in pat ients treated with dulagl utide, summar ies and analyses for incidence will be 
provi ded for each rando mized treatm ent, dulaglut ide3.0 m g/algorithm 1, dulaglutide 3.0 
H9X-MC-GBGJ Statistical Analysis Plan Version 1 Page 29
LY2189265mg/algori thm 2, dulagluti de4.5 m g/algori thm 1, dulaglut ide4.5 m g/algori thm 2, algorithm 1, 
algorithm [ADDRESS_614426] 6 weeks (titration phase), 
overall ,and by [CONTACT_765], to com pare the effects of the 4 different dose escalat ions ([ADDRESS_614427] igational doses) and e ffects of the [ADDRESS_614428] occurrence of nausea and/or vomiting 
will be summarized separately by [CONTACT_478740].
The m aximum  severi ty and durati on from baseline to Week 18 of nausea and/or vomiting 
TEAEs wil l be summarized by [CONTACT_478741] .
The time course plot on the initiation of nausea regardl ess of severit y (prevalence) will be 
generated for each treatment.  The y -axis is the % subjects with nausea and the x -axis is the time 
since the first dose .
If data warrant , a negative binomial model similar to the ra te of hy poglycemia analysis may be 
implemented for each of the aforement ioned parameter s.
A listing with treatm ent-emergent GI AEs of interest will be provi ded.
6.13.6. Treatment of Overdose
Astudy  drug overdose (more than the specified number of injections, whether for placebo or 
dulaglut idetreatm ent) will be reported as an AE.  This AE will be summarized only if it occurs 
with more than 3% of patients. Otherwise, only a data list ing will be generated including the 
actual dose data (Section 6.13.1 ) along with treatment overdose AE reported date.
6.13.7. Cardiovascular Safety
[IP_ADDRESS]. Cardiovascular Events
Listings and summaries of adjudicated and investigator -reported CV events will be provided.
The s ummary report for adjudicated and investigator -reported CV events will only be generated 
ifmore than 3% pati ents have the events. The test statist ics are detailed in Section 6.1.
[IP_ADDRESS]. Electrocardiograms
Heart rate (HR), PR interval (PR), and QT corrected for heart rate using QTcF are collected in 
triplicates. Prior to any  analysis, the ari thmetic mean fro m the three measures for the same 
param eter at t he same visit will be calculated and use for all subsequent analysis.  MMRM model 
detai led in Sect ion 6.1.forcontinuous variable analysis will be used to analyze each parameter in 
change from baseline .The treatm ent in the m odel will be placebo, d
ulaglut ide1.5 m g, 
dulaglut ide3.0 m g/algori thm 1, dulaglut ide3.0 m g/algorithm 2, dulagluti de4.5 m g/algori thm 1, 
dulaglut ide4.5 m g/algori thm 2.
The report sfor theseanalyses will include:
H9X-MC-GBGJ Statistical Analysis Plan Version 1 Page 30
LY2189265LS m eans and corresponding 95% CIs for each randomized treatment at each 
scheduled visit, and the difference in LS means, corresponding 95% CI along with 
p-value compared to placeb o and to dulaglut ide1.5 m g at the same visit.
LS m eans and corresponding 95% CIs of each parameter’s effect for a lgorithm 1, 
algorithm 2, and the diff erence between al gorithm 2 and a lgorithm 1 (using 
algorithm 1 as reference) at Week 6 (Visit 6).  These resul ts will notbe acquired
directly from the MMRM m odel. Rather, they  will be obtained from  the same 
model by [CONTACT_478742] 
d
ulaglut ide3.0 m g and dulagl utide4.5 m g.
LS m eans and corresponding 95% CIs of each parameter’s effect for d
ulagluti de
3.0, d
ulaglut ide4.5, and the difference between each co mbined treatment across 
algorithms and Pl acebo, and the difference between each co mbined treatment to 
Dula 1.5 at the same Week (Vi sit):  Week 8 (Visit 8), Week 10 (Visit 10) and 
Week 18 (Visit 12).  These results will be obtained through the same model by 
[CONTACT_478743].
The difference in LS means and the corresponding 95% CIs along with the p -
value between each maintenance visit ( Week 8/Visit 8, Week 10/Visit 10, Week 
18/Vi sit 12) and the end of t itration (Week 6/Visit 6) within the same treatment 
including the combined d
ulagl utide3.0 m g and 4.5 mg, and within the same 
algorithm will be presented.  Any  resul t related to combined treatment across 
algorithms and each a lgorithm at Vi sit 6 (Week 6) will  be formed by  [CONTACT_478744].
The thresho ldanalysis will only include HR, P R by  [CONTACT_478745], 
dulaglut ide3.0, and dulaglutide 4.5 m g.  The thresho ld isdefined in Table GBGJ . 3.
H9X-MC-GBGJ Statistical Analysis Plan Version 1 Page 31
LY2189265Table GBGJ .3. Heart Rate ,PR-Interval , and QTcF Abnormal Data
Parameter (Unit) Visit Threshold definition
HR (bpm) Baseline (Visit 1) >100, ≥[ADDRESS_614429] baseline >100 and CFB >15
PR (msec) Baseline (Visit 1) ≥[ADDRESS_614430] baseline ≥220
≥220 and (%CFB > 0 and ≤25%)
≥220 and (%CFB >25%)
QTcFBaseline (Visit 1) > 450 (Male) or > 470 (F emale)
> 480   
> [ADDRESS_614431] baseline > 450 (Male) or > 470 (F emale)
> 480   
> 500
>30 CFB
>60 CFB
Abbreviations:  QTcF = Fridericia’s corrected QT interval .
Note: CFB means change from baseline; and %CFB is the percentage change from baseline .
The qualitat ive summary related to the treatm ent-emergent cardiac conduction and rhyt hm 
abnorm alities will be reported by  [INVESTIGATOR_24258]. The abnormal ECG outcom es will be listed by 
[CONTACT_478746].
A non-ITP Bay esian m odel will be fitted detailed in Section [IP_ADDRESS] with the priors: 
α,β[i,t]~N(0,100) using [ZIP_CODE] MCMC samples wit h thin=10 and burn -in=[ADDRESS_614432] igational dulaglut idedose com pared to Dula 1.5 mg atWeek 18.
                       pr(Δ i-Δdula1.5mg < thresho ld) 
                       istands for dulaglut ide3.0mg/algori thm 1, dulaglut ide3.0mg/algorithm 2, 
dulaglut ide4.5 m g/algori thm 1, and dulagluti de4.5 m g/algori thm 2.
The thresho ld for this analysis will be 3bpm , 5bpm, 7bpm, 10 bpm .
The probabilit y for Week 26 will be assumed to be the same as Week 18 from this model. The 
algorithm com parison at Week 6 will be evaluated.
[IP_ADDRESS]. Vital Signs
Vital signs will  be listed for all randomized patient s.Prior to any analysis, the arithmet ic mean 
from the triplicates for the same parameter at the sam evisit will be calculated and use dfor all 
subsequent analysis. The change fro m baseline in p
ulse rate , systolic blood pressure, diastolic 
blood pressure (SBP, DBP )will be analyzed using a similar MMRM -based model as that 
described in Secti on [IP_ADDRESS] . The result will be reported in the same manner as that for heart 
rate listed in Sect ion [IP_ADDRESS] .The thresho ldanalyses will be summarized with the thresho ld 
defini tion is listed in Table GBGJ. 4.
H9X-MC-GBGJ Statistical Analysis Plan Version 1 Page 32
LY2189265Table GBGJ. 4. Abnormality Data for Heart Rate, Systolic Blood Pressure and 
Diastolic Blood Pressure
Parameter (unit) Visit Threshold definition
Pulse rate (bpm) Baseline (Visit 1) >100, ≥[ADDRESS_614433] baseline >100 and CFB > 15
SBP (mmHg) Baseline (Visit 1) ≥160, ≤[ADDRESS_614434] baseline ≥160 and  CFB ≥20
≤90 and CFB ≤ -20
DBP (mmHg) Baseline (Visit 1) ≥100, ≤[ADDRESS_614435] baseline ≥100 and CFB≥10
≤50 and CFB≤ -10
Abbreviations: bpm = beats per minute; CFB = change from baseline; DBP = diastolic blood pressure; SBP = 
systolic blood pressure
A non-ITP Bay esian m odel will be fitted detailed in Section [IP_ADDRESS] with the priors : 
α,β[i,t]~N(0,100) using [ZIP_CODE] MCMC samples wit h thin=10 and burn-in=[ADDRESS_614436] igational dulaglut idedose com pared to dulaglutide1.5 mg at Week 18.
                       pr(Δ i-Δdula1.5mg < thr eshold) 
istands for dulaglutide 3.0 mg/algorithm 1, dulaglutide 3.0 mg/algorithm 2, dulaglut ide 
4.5mg/algorithm 1, and dulaglut ide 4.5 mg/algorithm 2.
The thresho ld for this analysis will be [ADDRESS_614437] ional 
labora tory measures: estimated glo merul ar fil tration rate ( eGFR), Chronic Kidney Disease -
Epi[INVESTIGATOR_325328] (CKD -EPI), creatinin e, urine albumin/creat inine ratio (ACR ), by
[INVESTIGATOR_24258]. The ANOVA model will be fitted with treatment as a fixed effect on the ranked 
LOCF change fro m baseline data.
An ANCOVA model will be fitted with treatment as a fixed effect. The change fro m baseline in 
rank for each parameter will be the response variable.
The minimum eGFR value and the maximum creatinine, urine ACR will be used for baseline and 
post base line calculation to generate the shift table . Within treatm ent com parison will  be tested 
using generalized McNemar’s test.  The shift table will use eGFR cutoff (<30, 30- <60, 60 -<90, 
and ≥90 mL/min/1.73m2), creatinine ( ≤1ULN, >1 and ≤[ADDRESS_614438], 2 and ≤4ULN, a nd >4ULN), 
and UACR (<30, ( ≥30 and ≤300), and 300mg/g).  The overall rando mized treatment 
comparison will  be tested using a likelihood -ratio Chi -square test .The shift table for minimum 
eGFR for both baseline and post -first dose at Week [ADDRESS_614439]. Alisting will be provi ded wi th all d etected TEAE from these categories. 
6.13.9. Immunogenicity
Summaries dulagl utideanti-drug-antibodies (ADA )will be generated separately  for treatm ent-
emergent ADA , for detected ADA by [CONTACT_478747] 3% pati ents
developed an ADA .
The patient treatm ent-emergent ADA data will be listed.
6.13.10. Clinical Laboratory Evaluation
Amylase, lipase, calcitonin, eGFR, creatinine, urine ACR are included in Section [IP_ADDRESS] , 
Secti on [IP_ADDRESS] , and Secti on 6.13.[ADDRESS_614440] ion.For continuous (numeric) laboratory analytes, the rank on the change 
from baseline to endpoint (Week 18) will be analyzed as detailed in Section 6.1. For qualitative 
laboratory  analy tes, thenumber and percentages of patients with normal and abnormal  values 
will be analyzed using Chi -square tests or Fi sher’s exact test.
A summary  report and analysis for treatment -emergent abnormal laboratory  values (outsi de the 
reference ranges as appropriate) will be provided for each continuous analyte by [CONTACT_3148]. Shift 
tables of  the change fro m baseline value to the maximum post baseline value to Week 18 for 
selected analy tes using clinically  meaningful  threshol ds will  besummarized separately using 
generalized McNemar ’s test for within -treatm ent com parison and using likelihood ratio test for 
between -treatm ent (randomized) comparisons . A shift table for ALT, AST, ALP, GGT , total  
bilirubin, and direct bilirubin will be generated using cutoff ≤ 1ULN , (> [ADDRESS_614441] and <[ADDRESS_614442]), 
(≥3ULN and <5ULN), (≥5ULN and <[ADDRESS_614443]), ≥8U LN.
Laboratory  measurements will be listed by  [CONTACT_4676]. Addit ionallistings will be presented for 
laboratory  measurements that are outside the normal range and for measurements outside certain
prespecified clinically  relevant threshol dsif deemed appropria te.A listingof patients with either 
AST or ALT ≥3xULN , and total  bilirubin ≥2X ULN will also be provided.
6.14. Subgroup Analyses
Subgroup analyses of the treatm ent interacti on for important factors, including age group , race, 
gender, country , durati on of  diabetes (< median, ≥median) , baseline HbA1c (<8%, ≥8%), and 
BMI (< m edian, ≥median) , may be conducted for the primary  endpoint of HbA1c.   
Country  will
use the pool ed country .
These will be conducted using the MMRM with treatment, visit, subgroup, treatmen t-by- visit,
treatm ent-by-subgroup, visit -by-subgroup, and treatment -by-visit-by-subgroup as fixed effects,
and baseline as a covari ate. If the MMRM fails to converge, the corresponding analysis of
covari ance (ANCOVA) or ANOVA model (LOCF) will be used.
H9X-MC-GBGJ Statistical Analysis Plan Version 1 Page 34
LY2189265When analyzing baseline HbA1c as a subgroup, the baseline HbA1c will not be included as a
covari ate to avoi d colineari ty.
TEAE exceeding 5% will be summarized descriptively for the patients with the top quartile of 
the body  weight reducti on from baseline by  [CONTACT_1570] .
Other exploratory  subgroup analyses may  be perform ed as deemed appropriate.
6.15. Important Protocol Deviation s
Important protocol deviat ions will be listed for all rando mized patients and summarized by 
[CONTACT_3227].  All important deviat ionsrelated to study  inclusio n or exclusio n criteria, 
conduct of the trial, pat ient managements or patient assessment will be described. T he important
rotocol  deviat ions will be prospectively defined in the study -specific m onitoring requi rements . 
Some of the protocol  deviat ions that ma y not be prospectively iden tifiedmay later beconsidered 
important by [CONTACT_389793] , in which case will be also reported .The i mportant protocol 
deviat ion
swill be captured from the clinical trial database as well as an excel file managed by 
[CONTACT_478748] (CTM). The excel file generated by  [CONTACT_478749] 
a dom ain o f the study  data tabulati on m odel (STDM) as a source in addit ion to other necessary 
SDTM domains to define the PP popul ation.  The rationale for choosing certain important 
protocol  deviat ionsas exclusio nary from the PP popul ation will be based on their potenti al effect 
on the primary  efficacy  measures .  The decisio n and rationale for not reporting certain protocol 
deviat ions as important ones will be documented in the eTMF .  The fo llowing protocol  
condi tions will  resul t in exclusio n from the PPpopulat ion:
informed consent was never obtained
patients were randomized but the informed consent dat eis missing.
age <18 years oldat randomizat ion
p
atients have known ty pe 1 diabet es
patients who had any hematologic condit ion that may  have interfered with 
HbA1c measurement (eg, hemo lytic anemias, sickle -cell disease)
excluded medicine use prior to safet y follow-
up
oweight lossagents ,
oprohibited glucose -lowering agents (>14 days of use during the treatment 
period or any  time during the screening/lead -in period of sulfo nylureas, 
thiazolidinedio nes, al pha-glucosidase inhibitors, SGLT2 inhibitors, 
meglit inides, other GLP receptor agonists or DPP4 inhibitors, etc.)
o>14 day s use o f systemic glucocorti coid
patients have a nHbA1c < 7% or >10 %at Visit 1.
p
atients have a mi ssing HbA1c at baseline (both Visit 1 and Visit 3) or at 18 
weeks (Visit 12).
p
atients do not have an overall compliance with study  drug of at l east 75% up 
to 18weeks .
A co mplete list and summary  report of important protocol deviat ions will be generated.
H9X-MC-GBGJ Statistical Analysis Plan Version [ADDRESS_614444] three safet y interim analyses and one efficacy /safety  interim analysis will be conducted 
according to the specificat ions included in the protocol. The purpose of the safet y analyses will
be to m onitor the safet y and tol erabilit y of the 2 investigational dulaglut idedoses. Theinterim 
efficacy/safet y analysis will be conducted for internal clinical development planning purposes to 
enable preliminary dose -select ionfor Phase 3 planning.  The study  will not be stopped based on 
the efficacy  resul ts at this interim analysis. 
6.16.1. Assessment Committee
The interim analyses will be conducted under the auspi[INVESTIGATOR_26338] a nAssessment Committee (AC). 
The AC is authorized to review unblinded interim analyses.  Before any  interim analysis is 
perform ed, an AC will be established to control the dissem ination of the findings. Lilly 
representatives having direct contact [CONTACT_478750] n into the study  AC. Statist ical 
Analysis Center (SAC) will be authorized to evaluate unblinded interim analyses and prepare the 
reports for the AC t o revi ew. Study  sites m ayreceive informat ion about interim results ONLY if 
these results may have an impact on the safet y of patients in this trial .
The AC proceedings will be described in a nAC charter. Any change to the proceedings will be 
included in the AC charter and will not require a protocol or SAP am endment. The AC Charter 
describes the precise plan of the unblinded safet y monitoring andinterim stati stical analyses.
6.16.2. Interim Analyses
[IP_ADDRESS]. Timing of the Interim Analysis
The first safet y only interim analysis will occur after approximate ly [ADDRESS_614445] co mpleted 8
week s oftreatm ent. The AC will continue to evaluate patient safet y and tol erabilit y when 
approximately  30 patients and 60 patients complete 8 week s oftreatm ent.
The efficacy/safety  interim analysis will be conducted after approximately [ADDRESS_614446] 
completed the 18 -week treatm entperiod .
[IP_ADDRESS]. Evaluation Criteria
For safet y only interim analyses, the totalit y of the safet y data on AE s, SAE s, TEAE s, and 
AESI s, disposi tion, di scontin uation due to AEs, ECG, vital signs , ADA, GI AEs, cardiovascular 
events, and safet ylaboratory  analy tes will be evaluated. The analysis for each ment ioned 
param eter will be analyzed in the same way  as defined in this SAP.
For efficacy /safety  analysis , the AC will base their decision on the following criteriain addition 
tothe safet y parameters listed in the preceding paragraph :
HbA1c Criterion:
At least 80% probabilit y that at l east one dose of dulaglut ide3.[ADDRESS_614447] 0.2% compared to dulaglutide1.5 m g at Week 18, that i s, 
H9X-MC-GBGJ Statistical Analysis Plan Version 1 Page 36
LY2189265Pr(∆dula3.0 or dula4.5 - ∆dula1.5 < -0.2%) ≥80%]. The other threshold sof - 0.15% and -0.3% 
will be also be evaluated.   The probabilit y will  be at l east 55% at the end of the study .
Other efficacy endpo int at week 18:  change fro m baseline in body  weight, will  also be 
assessed relative to 1.5 mg as, Pr(∆dula3.0 or dula4.5 -
∆dula1.5 < thresho ldof -1 and -2 kg. 
Safety Parameters:
Heart rate from ECG, pulse rate from vital signs using change fro m baseline  to be 
assessed relative to placebo as , Pr( ∆dula3.0 or dula4.5 - ∆placebo < threshol dof 3, 5, 7, 10 bpm.
MMRM analysis results will be reported for change fro m baseline in HbA1c, body  
weight, sel ected ECG, vital signs, and pancreat icenzymes , too.
PK/PD exposure -response results will  be generated based on a separate PK/PD analysis 
plan by[CONTACT_31577]/PD group.
6.17. Planned Exploratory Analyses
Some of the pl anned exploratory  analyses are described in Sect ion 6.1. The remaining 
exploratory  expl oratory  analyses are described in this Sect ion.
The analysis of pat ients reaching HbA1c target ≤6.5% will use the same model as that for 
HbA1c target < 7.0% described in Section 6.11.[ADDRESS_614448] ing glucagon will be analyzed using MMRM 
described in Section 6.1.  If the norm ality assumpt ion is vio lated, appropriate data transform ation 
is needed prior to analysis.
Non-longitudinal cont inuous v ariables such as 6 -point SMPG, c-peptide, fasting insulin,  
HOMA2 -IR, and HOMA2 -%B will be a nalyzed using LOCF by [CONTACT_6486] a linear model with 
pooled country , treatm ent, baseline HbA1c strata as fixed effect sand the corresponding baseline 
value as a covariate.  A data transformat ion may be applied if data are not normally  distributed.
The 6-point SMPG consists of measurements befo re and 2 hours after each of 3 main meals 
within the same day. Each of the time point of the 6 -point SMPG will be analyzed separated.
6.18. Annual Report Analyses
The fo llowing reports are needed for the Development Safet y Update Report ( DSUR ): (1)
Estimated cumulat ive subject exposur e, (2)Cum ulative exposure to investigat ional drug, by  
[CONTACT_478751], 
(3)Exposure informat ion for ongoing clinical trials and clinical trials that completed during the 
reporting period, 
(4)Listing of subjects who died during the DSUR period, (5)Discontinuations
from the study due to adverse event , (6)Discont inuations fro m the study treatment due to 
adverse event during the DSUR Period.
H9X-MC-GBGJ Statistical Analysis Plan Version 1 Page 37
LY21892656.19. Clinical Trial Registry Analyses
Addit ional analyses will be performed for the purpose of fulfilling the Clinical Trial Registry  
(CTR )requirements.
Analyses provided for the CTR requirements include the fo llowing:
Summary  of adverse events , provided as a dataset which will be converted to an XML file .  
Both SAE and ‘Other’ A Eare summarized: by [CONTACT_1570], by  [CONTACT_6213].
An adverse event is considered ‘Serious’ whether it is a treatm ent em ergent 
adverse event (TEAE).
An adverse event is considered in the ‘Other’ category  if it is a TEAE butnot 
serious.  For each Seri ous AE and ‘Other’ AE, for each term and treatment 
group, the fo llowing are provided:
othe number of participants at risk of an event
othe number of participants who experienced each event term
othe number of events experienced
Consistent with www.ClinicalTrials.gov requirements, ‘Other’ AEs that occur 
in fewer than 5% of patients /subjects in every treatment group may n ot be 
included if a 5% thresho ld is chosen (5% is the minimum thresho ld).
AE reporti ng is consistent with other document disclosures for example, the 
CSR, manuscripts, and so forth.
H9X-MC-GBGJ Statistical Analysis Plan Version [ADDRESS_614449] to minimize bias 
while preparing for or conducting any summary or analysis o f the data for AC reports, data 
reviews, dose selection(interim efficacy/safet y only), and developi[INVESTIGATOR_007] /refining exposure 
analyse s.  Addi tionally, this pl an ident ifies personnel who will be unblinded during the study, 
including unblinding for the AC safet y only analyses, and safet y/efficacy interim analyses in 
support of the AC meet ings.
The access to subject treatment assignments w ill not be pro vided to the following personnel unt il 
datal ock i s authori zed f or the planned final analysis at the complet ion of theblinded study :
investi gator and si te personnel
Lilly personnel with direct site contact
Lilly personnel responsible for data entry  and data validat ion
Lilly study  team not in the AC and/or SAC
After datalock, the study  team  will be unblinded to the s tudy data to prepare for the analyse s for 
CSR. Invest igators can be provided treatment assignments for their subjects when unblin ding 
has occurred and the informat ion will not impact scient ific integrit y or introduce bias.
7.1. Operational Procedures
The rando mizat ion code (treatment assignment) will be stored in the Lilly interact ive web 
response system (IWRS) and will not be accessible to the blinded Lilly study  team , except for 
those pre -specified in the unblinding plan to be unblinded, unt il the final database lock (DBL). 
Members from the SAC, AC, and the study  global pati ent safet y(GPS) scientist may be 
unbli nded to data prior to th e DBL. The SAC, composed of Lilly unblinded statist ics personnel,
PK/PD scient ists and the PK/PD analysts (for efficacy /safety  interim analysis only) will forma 
separate team fro m the Lilly blinded team.  The SAC will obtain the rando mizat ion code fro m 
the unblinded inVent iv data movement group in order to generate unb linded TFLs for the AC.  
Membership is listed in Table GBGJ .5for each of the groups ment ioned above.
More specifically, the inVent iv data movement group will load CRF data, clinical laboratory  
resul ts, ECG, and IWRS data into the designed blinded and unblinded locat ions.  The blinded 
versio n of the data will then be provided to the blinded Lilly  study  team .  The unblinded data
will be provided to the SAC.  The inVent iv data movement gr oup i s not blinded, but is not 
involved in study -level act ivities.
H9X-MC-GBGJ Statistical Analysis Plan Version 1 Page 39
LY2189265Table GBGJ .5. Study H9X-MC-GBGJ Group Name [CONTACT_478763]: GPS = global patient safety ; PD = pharmacodynamics; PK = pharmacokinetics; SAE = significant
adverse events.
Periodically throughout the tri al until the DBL, blinded data will be transferred by [CONTACT_478752]  (SDTM) 
and Analysis Data Model (ADaM) dataset , AC reports , trial level safet y review reports , blinded 
AC reviews, TFL reviews, and CSR preparat ion.  To minimize bias during statist ical planning 
and data review, these transfers will be provi ded under the guidelines described in the fo llowing 
sections.
By [CONTACT_478753], the Lilly system will only allow unblinded personnel 
(unblinded statist ician and/or programmers) to access data that contains unblinding informa tion.
7.2. Site Level Unblinding
The procedure for site personnel to unblind an individual patient’s treatment assignment for an 
emergency is described in the protocol Section 7.3.Emergency  unblinding for adverse events 
may be performed by [CONTACT_478754]. When an IW RS Clinical Trial Study  
Manag ement System  (CT- SMS) i s used to unblind a patient ’s treatm ent assi gnment, the 
computer application will maintain the date, reason for unblinding, and the ident ificat ion of the 
person unblinding the treatment assignment.  All calls result ing in an unblinding event are
recorded and reported by  [CONTACT_208884].Group Name [CONTACT_478764] [CONTACT_478755], clinical trial mana ger , data sciences 
and solutions, global patient safety personnel , and study 
monitors, etc ., and non site direct contact [CONTACT_478756], statistician(s). However, per Lilly procedure, 
for patient saf ety, the study  GPS scientist will be 
unblinde d to SAE patient level data for patient safety .
Blinded Lilly  statistics group Lilly  statisticians and statistical analyst(s)
Statistical Analysis Center (Unblinded) Lilly  statisticians and statistical analyst(s)
Unblinded PK/PD team scientists (part of the SAC) Lilly  study  team pharmacokinetic/pharmacodynamics 
(PK/PD) scientists and analyst(s), etc.
Assessment Committee Lilly  Physicians, Statisticians, and GPS personnel
external to the study team
inVentiv data movement g roup inVentiv data movement representative
The program senior management Lilly  dulaglutide senior medical director or above 
H9X-MC-GBGJ Statistical Analysis Plan Version 1 Page 40
LY2189265The site monitor is responsible for verifying compliance wit h the blinding procedures at the 
investigat ive site and verifying that access to the patients’ treatment assignments remains
restri cted fro m the invest igator and site personnel in direct contact [CONTACT_57999] h patients.
The invest igator and site personnel are instructed to make every attempt to contact [CONTACT_478757] a patient’s treatment assignment is unblinded at the site.  The affiliate personnel 
docum ent th e unblinding records and inform the designat ed study  team  member, CTM ,who 
docum ents the overall unblinding records for the ent ire study . The documentation is filed in the 
study  files. A final Study  Unblinding Summary  will be prepared at the end of the study  (at the 
study  closeout).
7.3. Trial Level Safety Reviews
Periodic Tri al Level  Safety  Review (TLSR) summaries and list ings will be produced by  [CONTACT_478758] .
These summar ies will be blinded unt il after theDBL.  They  will contain neither rando mizat ion 
assignments nor post randomizat ion primary  endpoint HbA1c , dose inform ation, or PK data with 
the potenti al to unblind.  Blinding flags will be created in the central  laboratory  database, based 
upon the Alert and Blinding Cr iteria docum ent m aintained by  [CONTACT_478759] 
(CLO) group.  These flags will blind specific report data to the site and invest igators.  Data 
transferred to and exported fro m the clinical laboratory  resul ts will not be blinded to the Lilly 
team  or to the data m anagement of third party  organizat ion performing the labs.
The complete list of TLSR variables include overall AEs, serious adverse events (SAEs), TEAEs
AEs of special interest, labor atory  data, vi tal signs, ECG, discont inuat ions, co ncomitant 
medicat ions, and historical/pre -exist ing medical condi tions.
7.4. Assessment Committee Reports
The blinded Lilly  study  team  will remain blinded to randomizat ion assignments and potentially 
unblinding results unt il after the DBL.
The SAC statist ician is responsible for authorizing the access of Lilly personnel to unblinded 
data.  Every  attem pt shoul d be made to contact [CONTACT_478760].  A designated Interactive Web Response System 
(IWRS )representative , inVent iv data movement team or the replacement or thei r designee , will  
provi de all data transfers to the Lilly statisticsgroup based on the data transfer plan.
The study  project stati stician will be responsible for keepi[INVESTIGATOR_007] a running log of individuals given 
access to any  unblinded study  data.  Thi s log will  include the person’s name, tit le, date of 
unblinding, level o f unblinding ( that is, group or pati ent), and purpose of unblinding. This record 
will be stored in a secure area and w ill be stored in eTFM via the study  CTM after DBL.
Two ty pes of  interim analyses will be performed for this study :
H9X-MC-GBGJ Statistical Analysis Plan Version [ADDRESS_614450] 3 unblinded safet y only reviews. T he following personnel will be unblinded to 
the safet y data (efficac y measures will NOT be unblinded), in order to perform the safet y data 
analysis, prepare the AC safet y reports, and review/discuss the safet y resul ts:
The AC (determined in AC Charter )
Internal SAC (Lilly  study  personnel)
Computational Statist icians
Others:  No, but can be added upon AC Chair’s request
7.4.2. Efficacy/Safety Interim Report
[IP_ADDRESS]. Model Development
For the interim analysis o f efficacy, safety  and pharm acokinet ics, the fo llowing personnel will be 
unblinded to the pharm acokinetics rel ated data about 4 to 6 weeks after approximately 
80subjects complete 18week s oftreatm ent in order to develop the PK/PD m odeling and/or 
TFLs :
Internal SAC (Lilly  study  personnel)
Computational Statist icians
Internal Pharmacokinet ic Analysis Group (Lilly study  personnel , part of the SAC )
Pharmacokinet icist and Pharmacokinet ics Analysts
[IP_ADDRESS]. Reports Delivery
The following personnel will be unblinded to the efficacy , safet y
,and pharmacokinet ics data 
afterapproximately 120 subjects complete 18 -week treatment , in order to per form data analysis, 
prepare the interim reports, review the results, and discuss business related matters:
AC (determined in AC Charter)
Internal SAC (Lilly  personnel )or its delegate
Computational Statisticians
Internal Pharmacokinet ic Analysis Group (Lilly personnel , part of SAC )or its 
delegate
Pharmacokinet icist and Pharmacokinet ics Analysts
Others:  No, but can be added per the request from AC Chair and/or the program 
senior management
If PK reports needs more time to be generated, this interim review can be proceeded without PK 
data. A subsequent PK results review can be formed later after the results are available .
In addit ion, in order to perform the critical business development and the regulatory  interact ions, 
some personnel need to be unblinded to the related summary (group) level data , and possibly  
limited patient -level data after the interim safet y/efficacy analysis.  This unblinding requires 
H9X-MC-GBGJ Statistical Analysis Plan Version [ADDRESS_614451] ician shoul d be informed by  [CONTACT_478761] r for docum entati onpurpose .
7.5. Clinical Study Report
Prior to the final DBL, SDTM/ADaM datasets and draft TFLs will be produced by  [CONTACT_478762].
7.5.1. Prelock Unblinding
Lilly PK/PD scientists along wi th the SAC statist ician(s) who generate the data for PK/PD 
scientist swill access rando mizat ion codes prior to the final DBL.  Lilly PK/PD scient ists will 
obtain unblinding infor mation about 1 to 2 months before the DBL in order to perform PK/PD 
model-based analysis if deemed necessary.
7.5.2. End of Study Unblinding
After the final DBL, all  transfers of SDTM/ADaM files and TFLs to Lilly will be unblinded and 
will contain unblinded resul ts for all laboratory  param eters, PK data, and CRF data.
Immunogenicit y data will be obtained about 1 or 2 months after the final DBL in a separate 
transfer without overwrit ing the already locked database.
H9X-MC-GBGJ Statistical Analysis Plan Version 1 Page 43
LY21892658.References
Fu H, Manner D. Bay esian adaptive dose -finding studies wit h delayed responses. J Biopharm
Stat. 2010;20(5):[ADDRESS_614452] MG, Rosenkranz GK. Joint modeling of outcome, observation t ime, and missingness. J
Biopharm Stat . 2011;21(2):[ADDRESS_614453] analyses. Clin Trials . 2016 ;13(2) :161-
168.
Caum o A, Perseghin G, Brunani A, Luzi L. New insights on the simultaneous assessment of 
insulin sensit ivity and beta -cell function wit h the HOMA2 method. Diabete s Care . 2006 ;
29(12): 2733 -2734.
American Diabetes Associat ion Workgroup on Hypoglycemia .Defining and reporting 
hypoglycemia in diabetes: a report from the American Diabetes Association Workgroup on 
Hypoglycemia .Diabetes Care. 2005;28(5) :1245 –[ADDRESS_614454]. These analysis windows will be implemented in ADaM , and they  will not be 
used to overwrite or change the actual visit number that was reported by  [CONTACT_4179]. Furthermore, 
these analysis windows are separate from the allo wable range of days in the protocol’s schedule 
of events for visit s; they are not i ntended to be provided to sites so that there is no confusio n 
regarding the acceptable timing of patient visits.
There will be cases where a patien t has m ore than [ADDRESS_614455] itself that caused the investigator to repeat it on the same day .
H9X-MC-GBGJ Statistical Analysis Plan Version 1 Page 46
LY2189265Table APP1.1. Analysis Windows for the Selected Parameters
Screen ing and 
Lead -inTreamtent Period Safety Follow -
up
Visit V1 V2 V3 V4 V5 V6 V7 V8 V9 V10 V11 V12 V801
Week -2 -1 0 2 4 6 7 8 9 10 14 18 22
Day -14 -7 1 15 29 43 50 57 64 71 99 127 155
Vital signs, Height, 
Weight, BMI(-∞,-4) (- 10, -4) (- 3,1) (2,22) (23, 36) (37, A) (A+1, 53) (54, 60) (61,67) (68,85) (86,113) (114,B) (B+1, C)
ECG (-∞,1) (2,A) (A+1, 64) (65, 99) (100,B) (B+1, C)
6-point SMPG , Lipi[INVESTIGATOR_478696] (fasting) , c-
peptide, fasting insulin(-∞,1) (2,B)
Chemistry panel, 
urinary  analy sis, ACR, 
eGFR, Hematology(-∞,1) (2,B)
HbA1c, fasting glucose (-∞,-7) (-6,1) (2, A) (A+1,99) (100,B) (B+1, C)
(p) amylase, lipase, 
Serum calcitonin(-∞,-7) (-6,1) (2,A) (A+1,B) (B+1,C)
Fasting plasma 
glucagon(-∞,1) (2,A) (A+1,B)
Calcitonin (-∞,-7) (-6,1) (2,B)
Immunogenicity (-∞,1) (2, A) (A+1,B) (B+1, C)
Abbreviations:  ACR = a lbumin/creatinine ratio ; BMI = body mass index; ECG = electrocardiogram; eGFR = estimated glomerular filtration rate ;HbA1c = 
hemoglobin A1c; SMPG = self-monitored plasma glucose ; V = visit.
Windows represent the range of days, relative to the date of the first dose, associated with a particular time point.
Note: (day1, day2), are inclusive.
      A, B, C: actual day on which eac h patient individually ends the titration phase, maintenance phase , or safety follow -up. If the actual day is missing, the
planned day of 46, 141, and  158 will be used to represent the end of the titra tion phase, maintenance phase, or safety follow -up.
Day 1: The day  of the first dosing date or the day of the randomization date if first dosing date is missing
*When creating windows for the baseline, use the last non -missing pre -first dosing value.
The above analysis windows will not be used for analysis of hypoglycemia or compliance over time.
Any other parameters not listed in this table will use the site or investigator reported visit measurement directly without a pplying the visit window.
[COMPANY_003]Leo Document ID = fd7b28a3-2e71-452d-9516-82fbf127c4af
Approver: 
Approval Date & Time: 08-Dec-2016 20:45:48 GMT
Signature [CONTACT_32869]: Approved